Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company has market cap of $1.08 billion. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It currently has negative earnings. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia.
Among 5 analysts covering Fibria Celulose (NYSE:FBR), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Fibria Celulose has $17 highest and $13.5000 lowest target. $15.07’s average target is 8.97% above currents $13.83 stock price. Fibria Celulose had 8 analyst reports since July 24, 2015 according to SRatingsIntel. As per Friday, July 24, the company rating was upgraded by Morgan Stanley. The stock has “Neutral” rating by Goldman Sachs on Monday, December 14. The firm has “Neutral” rating given on Thursday, July 21 by Bank of America. Zacks downgraded Fibria Celulose S.A. (NYSE:FBR) on Monday, August 10 to “Buy” rating. The stock of Fibria Celulose S.A. (NYSE:FBR) earned “Buy” rating by Citigroup on Friday, October 9. The company was upgraded on Wednesday, June 14 by J.P. Morgan. On Monday, August 14 the stock rating was upgraded by Citigroup to “Buy”.
Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on February, 27. They expect $-1.29 EPS, down 514.29% or $1.08 from last year’s $-0.21 per share. After $-1.21 actual EPS reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts 6.61% negative EPS growth.
Venbio Select Advisor Llc holds 4.88% of its portfolio in Dermira, Inc. for 1.33 million shares. Nea Management Company Llc owns 3.51 million shares or 3.72% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 2.31% invested in the company for 140,000 shares. The California-based Foresite Capital Management Ii Llc has invested 1.81% in the stock. Abingworth Llp, a United Kingdom-based fund reported 70,000 shares.
The stock increased 1.09% or $0.28 during the last trading session, reaching $25.88. About 51,338 shares traded. Dermira, Inc. (DERM) has declined 7.44% since December 1, 2016 and is downtrending. It has underperformed by 24.14% the S&P500.
Investors sentiment is 1.19 in Q2 2017. Its the same as in 2017Q1. It is the same, as 19 investors sold Fibria Celulose S.A. shares while 40 reduced holdings. only 35 funds opened positions while 35 raised stakes. 33.18 million shares or 3.49% more from 32.06 million shares in 2017Q1 were reported. Creative Planning, Kansas-based fund reported 25,454 shares. Pinebridge Investments L P reported 57,000 shares. Bard Assocs Inc invested 0.4% of its portfolio in Fibria Celulose S.A. (NYSE:FBR). Schwab Charles Investment, California-based fund reported 88,056 shares. Moreover, Prudential Fincl has 0% invested in Fibria Celulose S.A. (NYSE:FBR). Bankshares Of Montreal Can invested in 1,001 shares or 0% of the stock. Morgan Stanley invested in 76,186 shares. Mcf Advsrs Limited Com stated it has 3,000 shares or 0.01% of all its holdings. Pictet Asset Mgmt holds 2.84 million shares. Fincl Architects accumulated 0% or 12 shares. Colorado-based Cetera Advsrs Limited Liability Company has invested 0.06% in Fibria Celulose S.A. (NYSE:FBR). Daiwa Secs Grp Incorporated Inc reported 93,200 shares. 29,157 are held by Wells Fargo & Communication Mn. Verition Fund Ltd accumulated 0.04% or 44,232 shares. Credit Suisse Ag accumulated 40,321 shares or 0% of the stock.
The stock decreased 0.43% or $0.06 during the last trading session, reaching $13.83. About 265,861 shares traded. Fibria Celulose S.A. (NYSE:FBR) has risen 16.20% since December 1, 2016 and is uptrending. It has underperformed by 0.50% the S&P500.
The post Fibria Celulose S.A (FBR) Gets Credit Suisse Lower Rating; Dermira (DERM) Sentiment Is 1.39 appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2017/12/01/fibria-celulose-s-a-fbr-gets-credit-suisse-lower-rating-dermira-derm-sentiment-is-1-39/
No comments:
Post a Comment